Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 10/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.63 |
| ▸ | OGFRL1 | Q5TC84 | 11/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10216364 | 0.85 | OPRL1 (0.74) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL1270574 | 0.82 | OPRL1 (0.72) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL4546408 | 0.81 | OPRL1 (0.71) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL12028178 | 0.80 | OPRL1 (0.77) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL1271715 | 0.80 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL551174 | 0.77 | OPRM1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL1270541 | 0.75 | OPRL1 (0.65) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL1272240 | 0.74 | OPRL1 (0.61) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL3612375 | 0.69 | OPRM1 (0.61) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL1861746 | 0.68 | OPRL1 (0.57) | OPRL1OPRM1OPRK1OPRD1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108575-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
| WO-2008089201-A2 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE AS ORL-1 LIGANDS | PURDUE PHARMA L.P. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108575-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, P2RX4, TRPA1 | OPRL1 6/4885OPRM1 17/4885OPRK1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.